The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Advice for physicians when managing a pregnant patient with a hematologic malignancy
Daan Dierickx, MD, PhD, KU Leuven and University Hospitals Leuven, Leuven, Belgium, discusses the key takeaways from a recent paper outlining expert opinion on the diagnosis and treatment of hematologic malignancies during pregnancy. He emphasizes that, ideally, patients should be treated in specialized centers by multidisciplinary teams that include both hematologists and gynecologists. Prof. Dierickx also highlights valuable resources for physicians caring for a pregnant patient with a hematologic malignancy, including an advisory board to which they can turn for prompt guidance and support. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, I think the most important… there are actually three messages. The first is that we can treat a lot of patients, so we have insights. But the second, that is also important, we need to do it in specialized centers. For example, in Leuven, we have the… we treat together with the gynecologist. So we really see the patient together. When the patient comes for the therapy, we see them also together...
Yeah, I think the most important… there are actually three messages. The first is that we can treat a lot of patients, so we have insights. But the second, that is also important, we need to do it in specialized centers. For example, in Leuven, we have the… we treat together with the gynecologist. So we really see the patient together. When the patient comes for the therapy, we see them also together. We see everything is okay with the mom. Everything is okay with the blood of the mom. Everything is okay with the baby. And then we decide together we’re going to give the chemotherapy. We’re going to proceed. If it’s not safe, we have to reconsider. So it’s very important to have an experience both in the hematological oncology setting as in the gynecological setting.
And the third one is that the treatment should be in specialized centers. That’s a bit together with the former, that if you only treat one pregnant patient in five years, I think it’s better to refer. And there is also the International Network on Cancer, Infertility, and Pregnancy, the INCIP. It’s a kind of platform in which actually every pregnant patient can be introduced by their treating physician. And the treating physician can ask for advice. We have a patient, for example, 40 weeks pregnant with that malignancy, that stage. How should I treat these patients? And then in the INCIP, there’s an, it’s called the ABCIP Advisory Board, which actually consists of members of all disciplines, hematologists, gynecologists, neonatologists, radiotherapists, and so on. And actually, in two or three days, advice is given. So we are treating this…we would recommend to treat this patient like this. So the register has actually two aims to help physicians to treat their patients, pregnant patients with oncological diseases on the one hand, and on the other hand, it’s a real registration tool so that we know how common is cancer and pregnancy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
